Author + information
- Norihiko Kamioka1,
- Vasilis Babaliaros2,
- Michael Morse3,
- Tiberio Frisoli4,
- Jose Miguel Iturbe1,
- Frank Corrigan2,
- Jessica Forcillo1,
- Hope Caughron1,
- Andy Dong1,
- Chandan Devireddy1,
- William O'Neill5,
- Gaetano Paone5,
- Dee Dee Wang5,
- Vinod Thourani6 and
- Adam Greenbaum5
- 1Emory University, Atlanta, Georgia, United States
- 2Emory University School of Medicine, Atlanta, Georgia, United States
- 3St Thomas Hospital, Nashville, Tennessee, United States
- 4Henry Ford, Detroit, Michigan, United States
- 5Henry Ford Hospital, Detroit, Michigan, United States
- 6Emory University Hospital Midtown, Atlanta, Georgia, United States
Adequacy of echocardiographic findings and clinical outcome after transcatheter mitral valve-in-valve replacement for degenerative bioprosthesis is not fully understood.
We retrospectively identified patients who underwent mitral valve replacement via either surgical or transcatheter for degenerative mitral bioprosthesis at three US institution. We compared echocardiographic findings and clinical outcome of patients who had mitral valve-in-valve with those of patients who underwent second surgical mitral valve replacement.
58 patients underwent transcatheter mitral valve replacement (TMVR) and 57 patients underwent surgical mitral valve replacement (SMVR). Mean age and the Society of Thoracic Surgeons-Predicted Risk of Mortality (STS-PROM) were significantly higher in patients with TMVR than in those with SMVR (Age 74.8±11.1years vs 65.9±14.2years, P=0.002; STS-PROM 13.6±8.2% vs 8.9±9.8%, P<0.0001, respectively). Although mean transmitral pressure gradient (MPG) tended to be higher in the TMVR group (6.5±2.8 vs 5.3±2.5, P=0.03), mitral valve area (MVA) and mitral regurgitation grade at discharge were similar between the TMVR group and SMVR group (MVA 2.6±0.8 vs 3.0±1.2, P=0.47; MR (≥mild) 9.6% vs 10.3%, P=0.92, respectively), achieving similar 1-year survival rate (TMVR 83.5% vs SMVR 76.9%, P=0.23).
Echocardiographic findings after TMVR for degenerative mitral bioprosthesis were acceptable when compared with those after SMVR, achieving similar one-year survival between the TMVR and the SMVR group.
STRUCTURAL: Valvular Disease: Mitral